Vertex Pharmaceuticals’ pioneering cell therapy for type 1 diabetes, zimislecel, demonstrated promising Phase 1/2 data showing that 10 of 12 patients achieved insulin independence at least one year post-treatment with effective blood glucose control in all participants. The therapy potentially offers a transformative approach to managing type 1 diabetes by reducing or eliminating reliance on exogenous insulin. Vertex expects to complete pivotal study enrollment imminently and move forward with regulatory submissions. Concurrently, the company reported reductions in hypoglycemic episodes with its islet cell therapy in early trials, reinforcing its commitment to innovative cell-based diabetes treatments.